<DOC>
	<DOCNO>NCT01929759</DOCNO>
	<brief_summary>In study use multi-modal imaging approach MRS fMRI comprehensively assess biological change brain associate EFV-based regimen ( EFV/FTC/TDF ) , specifically alteration brain circuitry , function local neurochemistry , correlation neuropsychological function . In cohort HIV-infected patient clinically stable commonly use regimen EFV/emtricitabine ( FTC ) /truvada ( TDF ) Atripla , propose replace EFV component new integrase inhibitor , elvitegravir ( EVG ) boost cobicistat ( COBI ) , give EVG/COBI/FTC/TDF Single Tablet Regimen ( STR ) evaluate EFV-related neural alteration . This multidisciplinary study involve team infectious disease expert field HIV , neuroradiologists expertise fMRI MRS technique study various central nervous system psychiatric disorder psychiatrist experience expertise research abnormality affective motivational processing context neuropsychiatric disorder . We utilize establish clinical research platform Infectious Disease outpatient clinical practice Brigham Women 's Hospital , currently many ongoing HIV-related study large panel HIV-infected patient motivate involve clinically relevant research . We propose use advanced neuroimaging measure biologically change brain associated long-term EFV use follow specific aim : 1 . Determine change neurometabolites measure MRS brain associate long-term EFV use 2 . Assess alteration neural activity correlate affective symptom associate EFV v STR use use fMRI , association change neurometabolites assess MRS , change cognition assess Trail Making Digit Substitution Tests . 3 . Determine change emotion , cognition sleep quality switch EFV STR , correlate subject treatment preference . This clinical study extend current understanding EFV neurotoxicity define nature biological change . Further elucidation neurobiological underpinnings EFV-induced CNS toxicity clinical relevance improve quality life drug adherence HIV-infected patient ART , especially among old patient baseline neuropsychiatric disorder , baseline vulnerable neurocognitive decline long-term HIV infection .</brief_summary>
	<brief_title>Advanced Neuroimaging Evaluation Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch Elvitegravir-based Regimen</brief_title>
	<detailed_description />
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Chronic HIVinfected individual suppressive regimen EFV/FTC/TDF , least 6 month Undetectable HIV1 RNA virus load least 6 month No coinfections active hepatitis B C Presence least moderate symptom 2 3 subcores DASS No known active HIVrelated nonHIV relate CNS infection Estimated glomerular filtration rate ( EGFR ) &gt; 60 ml/min Consent switch EVG/COBI/FTC/TDF Ages 18 65 History CNS opportunistic infection active CNS infection History severe psychiatric disorder ( exclude depression anxiety ) History chronic neurological disorder , epilepsy multiple sclerosis History current significant substance abuse dependence and/or heavy alcohol use ( &gt; 12 oz/wk ) Any woman may pregnant ( positive urine pregnancy test unprotected sex 2 week prior scan ) know pregnant Contraindications undergo fMRI , include metallic implant , claustrophobia , medical condition medication significantly affect cerebral blood flow function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>neurocognitive symptom</keyword>
	<keyword>efavirenz</keyword>
	<keyword>elvitegravir</keyword>
	<keyword>neurometabolites</keyword>
</DOC>